Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy.

MLA

Dewaraja, Yuni K., et al. “Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy.” Journal of Nuclear Medicine, vol. 55, no. 7, July 2014, pp. 1047–53. EBSCOhost, https://doi.org/10.2967/jnumed.113.136044.

APA

Dewaraja, Y. K., Schipper, M. J., Jincheng Shen, Smith, L. B., Murgic, J., Savas, H., Youssef, E., Regan, D., Wilderman, S. J., Roberson, P. L., Kaminski, M. S., & Avram, A. M. (2014). Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy. Journal of Nuclear Medicine, 55(7), 1047–1053. https://doi.org/10.2967/jnumed.113.136044

Chicago

Dewaraja, Yuni K., Matthew J. Schipper, Jincheng Shen, Lauren B. Smith, Jure Murgic, Hatice Savas, Ehab Youssef, et al. 2014. “Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy.” Journal of Nuclear Medicine 55 (7): 1047–53. doi:10.2967/jnumed.113.136044.